S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
30 Days of MarketBeat All Access Free (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
30 Days of MarketBeat All Access Free (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
30 Days of MarketBeat All Access Free (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
30 Days of MarketBeat All Access Free (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:APTO

Aptose Biosciences (APTO) Stock Forecast, Price & News

$3.05
-0.06 (-1.93%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.02
$3.21
50-Day Range
$3.04
$5.04
52-Week Range
$2.91
$11.85
Volume
36,714 shs
Average Volume
27,728 shs
Market Capitalization
$22.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.50

Aptose Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,162.3% Upside
$38.50 Price Target
Short Interest
Healthy
1.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of Aptose Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.65) to ($7.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

91st out of 963 stocks

Biological Products, Except Diagnostic Industry

9th out of 159 stocks


APTO stock logo

About Aptose Biosciences (NASDAQ:APTO) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

APTO Price History

APTO Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Expert Ratings for Aptose Biosciences
Closing Bell: Aptose Biosciences Inc down on Tuesday (APS)
Aptose Biosciences (NASDAQ: APTO)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
APTO - Aptose Biosciences Inc.
JonesTrading Keeps Their Buy Rating on Aptose Biosciences (APTO)
Analyst Expectations for Aptose Biosciences's Future
See More Headlines
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APTO
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.50
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+1,162.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-41,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.13 per share

Miscellaneous

Free Float
6,604,000
Market Cap
$22.27 million
Optionable
Optionable
Beta
1.38
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.













APTO Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings
or view top-rated stocks.

What is Aptose Biosciences' stock price forecast for 2023?

6 Wall Street research analysts have issued 1-year target prices for Aptose Biosciences' stock. Their APTO share price forecasts range from $12.00 to $120.00. On average, they predict the company's stock price to reach $38.50 in the next twelve months. This suggests a possible upside of 1,162.3% from the stock's current price.
View analysts price targets for APTO
or view top-rated stocks among Wall Street analysts.

How have APTO shares performed in 2023?

Aptose Biosciences' stock was trading at $8.70 on January 1st, 2023. Since then, APTO shares have decreased by 64.9% and is now trading at $3.05.
View the best growth stocks for 2023 here
.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a decline in short interest in August. As of August 31st, there was short interest totaling 37,800 shares, a decline of 7.1% from the August 15th total of 40,700 shares. Based on an average daily trading volume, of 46,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.8% of the shares of the company are sold short.
View Aptose Biosciences' Short Interest
.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our APTO earnings forecast
.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($2.27) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by $0.18.

When did Aptose Biosciences' stock split?

Aptose Biosciences shares reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include DRW Securities LLC (0.63%), Carlson Capital L P (0.11%), Goldman Sachs Group Inc. (0.04%) and Voss Capital LLC (0.02%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends
.

How do I buy shares of Aptose Biosciences?

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $3.05.

How much money does Aptose Biosciences make?

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $22.27 million. The biotechnology company earns $-41,820,000.00 in net income (profit) each year or ($7.8173) on an earnings per share basis.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.

This page (NASDAQ:APTO) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -